Form 4: BridgeBio Officer Sells Shares Under 10b5-1 Plan

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, sold 2,000 shares of common stock for $74.26 per share under a pre-arranged 10b5-1 plan.

Summary

• Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., disposed of 2,000 shares of common stock.
• The transaction occurred on December 8, 2025, at a price of $74.26 per share.
• This sale was executed pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on September 8, 2025.
• Following the transaction, Apuli beneficially owns 130,297 shares of BridgeBio Pharma common stock.

Sentiment

Score: 5

Explanation: A routine insider sale under a pre-arranged 10b5-1 plan, which is generally considered neutral as it reflects pre-planned liquidity management rather than a reaction to new company developments.

Negatives

• Chief Accounting Officer Maricel Apuli disposed of 2,000 shares of common stock.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This Form 4 reports a routine insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its execution under a 10b5-1 plan suggests it is for personal financial planning rather than a reflection of company performance, thus having a neutral impact.

Key Dates

Recommendation

This Form 4 reports a routine insider sale by the Chief Accounting Officer under a pre-established 10b5-1 plan. Such sales are typically for personal financial planning and do not inherently signal a change in the company's fundamentals or future prospects. Therefore, it does not provide a basis for changing an existing investment thesis, warranting a 'hold' recommendation.

Keywords

BridgeBio Pharma, BBIO, insider transaction, Form 4, stock sale, officer, Maricel Apuli, 10b5-1 plan